nodes	percent_of_prediction	percent_of_DWPC	metapath
Bimatoprost—AKR1C3—uterine cancer	0.451	1	CbGaD
Bimatoprost—AKR1C3—Medroxyprogesterone Acetate—uterine cancer	0.354	0.832	CbGbCtD
Bimatoprost—AKR1C3—Doxorubicin—uterine cancer	0.0715	0.168	CbGbCtD
Bimatoprost—PTGFR—corpus luteum—uterine cancer	0.0164	0.34	CbGeAlD
Bimatoprost—AKR1C3—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.00294	0.118	CbGpPWpGaD
Bimatoprost—PTGER3—myometrium—uterine cancer	0.00226	0.0467	CbGeAlD
Bimatoprost—Macular oedema—Medroxyprogesterone Acetate—uterine cancer	0.00217	0.0457	CcSEcCtD
Bimatoprost—AKR1C3—Synthesis of bile acids and bile salts via 24-hydroxycholesterol—AKR1C1—uterine cancer	0.00206	0.0826	CbGpPWpGaD
Bimatoprost—AKR1C3—Synthesis of bile acids and bile salts via 27-hydroxycholesterol—AKR1C1—uterine cancer	0.00195	0.0782	CbGpPWpGaD
Bimatoprost—AKR1C3—Podofilox—Etoposide—uterine cancer	0.00192	1	CbGdCrCtD
Bimatoprost—PTGER1—renal system—uterine cancer	0.00188	0.0388	CbGeAlD
Bimatoprost—PTGFR—myometrium—uterine cancer	0.00181	0.0374	CbGeAlD
Bimatoprost—PTGER3—smooth muscle tissue—uterine cancer	0.00171	0.0353	CbGeAlD
Bimatoprost—PTGER3—renal system—uterine cancer	0.00165	0.034	CbGeAlD
Bimatoprost—PTGER1—female reproductive system—uterine cancer	0.0015	0.0311	CbGeAlD
Bimatoprost—AKR1C3—myometrium—uterine cancer	0.00147	0.0304	CbGeAlD
Bimatoprost—PTGER3—uterus—uterine cancer	0.00147	0.0303	CbGeAlD
Bimatoprost—PTGER1—female gonad—uterine cancer	0.00137	0.0283	CbGeAlD
Bimatoprost—PTGFR—smooth muscle tissue—uterine cancer	0.00137	0.0283	CbGeAlD
Bimatoprost—AKR1C3—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C1—uterine cancer	0.00134	0.0537	CbGpPWpGaD
Bimatoprost—PTGER3—female reproductive system—uterine cancer	0.00132	0.0272	CbGeAlD
Bimatoprost—PTGER3—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.0013	0.0518	CbGpPWpGaD
Bimatoprost—AKR1C3—Retinoid metabolism and transport—AKR1B10—uterine cancer	0.00128	0.0513	CbGpPWpGaD
Bimatoprost—AKR1C3—Synthesis of bile acids and bile salts—AKR1C1—uterine cancer	0.00122	0.0489	CbGpPWpGaD
Bimatoprost—PTGER3—female gonad—uterine cancer	0.0012	0.0248	CbGeAlD
Bimatoprost—PTGFR—uterus—uterine cancer	0.00117	0.0242	CbGeAlD
Bimatoprost—AKR1C3—uterine cervix—uterine cancer	0.00114	0.0236	CbGeAlD
Bimatoprost—AKR1C3—smooth muscle tissue—uterine cancer	0.00111	0.023	CbGeAlD
Bimatoprost—AKR1C3—decidua—uterine cancer	0.00109	0.0225	CbGeAlD
Bimatoprost—PTGFR—female reproductive system—uterine cancer	0.00105	0.0218	CbGeAlD
Bimatoprost—AKR1C3—endometrium—uterine cancer	0.00103	0.0214	CbGeAlD
Bimatoprost—Hirsutism—Progesterone—uterine cancer	0.00101	0.0212	CcSEcCtD
Bimatoprost—AKR1C3—mammalian vulva—uterine cancer	0.001	0.0207	CbGeAlD
Bimatoprost—AKR1C3—Bile acid and bile salt metabolism—AKR1C1—uterine cancer	0.00097	0.0388	CbGpPWpGaD
Bimatoprost—PTGFR—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.000969	0.0388	CbGpPWpGaD
Bimatoprost—PTGFR—female gonad—uterine cancer	0.000959	0.0198	CbGeAlD
Bimatoprost—AKR1C3—uterus—uterine cancer	0.000952	0.0197	CbGeAlD
Bimatoprost—PTGER1—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.000948	0.0379	CbGpPWpGaD
Bimatoprost—Hirsutism—Medroxyprogesterone Acetate—uterine cancer	0.000912	0.0192	CcSEcCtD
Bimatoprost—AKR1C3—Retinoid metabolism and transport—AKR1C1—uterine cancer	0.000874	0.035	CbGpPWpGaD
Bimatoprost—AKR1C3—female gonad—uterine cancer	0.000779	0.0161	CbGeAlD
Bimatoprost—AKR1C3—vagina—uterine cancer	0.000774	0.016	CbGeAlD
Bimatoprost—PTGER3—lymph node—uterine cancer	0.000771	0.0159	CbGeAlD
Bimatoprost—AKR1C3—Diseases associated with visual transduction—AKR1B10—uterine cancer	0.000654	0.0262	CbGpPWpGaD
Bimatoprost—Skin discolouration—Progesterone—uterine cancer	0.000648	0.0136	CcSEcCtD
Bimatoprost—Dinoprostone—CYP11A1—uterine cancer	0.000621	0.659	CrCbGaD
Bimatoprost—PTGFR—lymph node—uterine cancer	0.000616	0.0127	CbGeAlD
Bimatoprost—Cystitis noninfective—Progesterone—uterine cancer	0.000571	0.012	CcSEcCtD
Bimatoprost—Cystitis—Progesterone—uterine cancer	0.000565	0.0119	CcSEcCtD
Bimatoprost—Bladder pain—Progesterone—uterine cancer	0.000529	0.0111	CcSEcCtD
Bimatoprost—Cystitis noninfective—Medroxyprogesterone Acetate—uterine cancer	0.000518	0.0109	CcSEcCtD
Bimatoprost—Cystitis—Medroxyprogesterone Acetate—uterine cancer	0.000512	0.0108	CcSEcCtD
Bimatoprost—AKR1C3—lymph node—uterine cancer	0.000501	0.0104	CbGeAlD
Bimatoprost—Bladder pain—Medroxyprogesterone Acetate—uterine cancer	0.000479	0.0101	CcSEcCtD
Bimatoprost—Visual disturbance—Progesterone—uterine cancer	0.000448	0.00942	CcSEcCtD
Bimatoprost—AKR1C3—Diseases associated with visual transduction—AKR1C1—uterine cancer	0.000446	0.0179	CbGpPWpGaD
Bimatoprost—Arthritis—Progesterone—uterine cancer	0.000437	0.00919	CcSEcCtD
Bimatoprost—Diplopia—Progesterone—uterine cancer	0.000425	0.00893	CcSEcCtD
Bimatoprost—Visual disturbance—Medroxyprogesterone Acetate—uterine cancer	0.000406	0.00854	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—AKR1B10—uterine cancer	0.000401	0.0161	CbGpPWpGaD
Bimatoprost—Infection—Carboplatin—uterine cancer	0.000395	0.0083	CcSEcCtD
Bimatoprost—Liver function test abnormal—Progesterone—uterine cancer	0.000392	0.00824	CcSEcCtD
Bimatoprost—Nasopharyngitis—Progesterone—uterine cancer	0.00038	0.00799	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—AKR1B1—uterine cancer	0.000373	0.0149	CbGpPWpGaD
Bimatoprost—Asthma—Progesterone—uterine cancer	0.000367	0.00772	CcSEcCtD
Bimatoprost—Bronchitis—Progesterone—uterine cancer	0.000353	0.00742	CcSEcCtD
Bimatoprost—Dry skin—Medroxyprogesterone Acetate—uterine cancer	0.000353	0.00742	CcSEcCtD
Bimatoprost—Nasopharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000344	0.00724	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Progesterone—uterine cancer	0.000341	0.00717	CcSEcCtD
Bimatoprost—Pain—Carboplatin—uterine cancer	0.00034	0.00715	CcSEcCtD
Bimatoprost—Asthma—Medroxyprogesterone Acetate—uterine cancer	0.000333	0.00699	CcSEcCtD
Bimatoprost—Skin discolouration—Etoposide—uterine cancer	0.000331	0.00697	CcSEcCtD
Bimatoprost—Depression—Progesterone—uterine cancer	0.000326	0.00686	CcSEcCtD
Bimatoprost—Dinoprostone—CYP19A1—uterine cancer	0.000321	0.341	CrCbGaD
Bimatoprost—Bronchitis—Medroxyprogesterone Acetate—uterine cancer	0.00032	0.00673	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Medroxyprogesterone Acetate—uterine cancer	0.000309	0.0065	CcSEcCtD
Bimatoprost—Inflammation—Etoposide—uterine cancer	0.000309	0.00649	CcSEcCtD
Bimatoprost—Sinusitis—Progesterone—uterine cancer	0.000307	0.00646	CcSEcCtD
Bimatoprost—Urine abnormality—Epirubicin—uterine cancer	0.000303	0.00637	CcSEcCtD
Bimatoprost—Depression—Medroxyprogesterone Acetate—uterine cancer	0.000296	0.00622	CcSEcCtD
Bimatoprost—Rhinitis—Progesterone—uterine cancer	0.000295	0.00619	CcSEcCtD
Bimatoprost—Pharyngitis—Progesterone—uterine cancer	0.000292	0.00613	CcSEcCtD
Bimatoprost—Oedema peripheral—Progesterone—uterine cancer	0.000289	0.00609	CcSEcCtD
Bimatoprost—Connective tissue disorder—Progesterone—uterine cancer	0.000289	0.00607	CcSEcCtD
Bimatoprost—Lacrimation—Epirubicin—uterine cancer	0.000285	0.006	CcSEcCtD
Bimatoprost—Urine analysis abnormal—Epirubicin—uterine cancer	0.000285	0.006	CcSEcCtD
Bimatoprost—Visual impairment—Progesterone—uterine cancer	0.000283	0.00595	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Epirubicin—uterine cancer	0.000282	0.00593	CcSEcCtD
Bimatoprost—Urine abnormality—Doxorubicin—uterine cancer	0.00028	0.0059	CcSEcCtD
Bimatoprost—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.00585	CcSEcCtD
Bimatoprost—Liver function test abnormal—Dactinomycin—uterine cancer	0.000277	0.00583	CcSEcCtD
Bimatoprost—Eye disorder—Progesterone—uterine cancer	0.000275	0.00577	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—AKR1C1—uterine cancer	0.000274	0.011	CbGpPWpGaD
Bimatoprost—Angiopathy—Progesterone—uterine cancer	0.000267	0.00561	CcSEcCtD
Bimatoprost—Mediastinal disorder—Progesterone—uterine cancer	0.000265	0.00557	CcSEcCtD
Bimatoprost—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000264	0.00556	CcSEcCtD
Bimatoprost—Urine analysis abnormal—Doxorubicin—uterine cancer	0.000264	0.00555	CcSEcCtD
Bimatoprost—Lacrimation—Doxorubicin—uterine cancer	0.000264	0.00555	CcSEcCtD
Bimatoprost—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000262	0.00551	CcSEcCtD
Bimatoprost—Connective tissue disorder—Medroxyprogesterone Acetate—uterine cancer	0.000262	0.0055	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Doxorubicin—uterine cancer	0.000261	0.00549	CcSEcCtD
Bimatoprost—Keratitis—Epirubicin—uterine cancer	0.000259	0.00544	CcSEcCtD
Bimatoprost—Visual impairment—Medroxyprogesterone Acetate—uterine cancer	0.000257	0.00539	CcSEcCtD
Bimatoprost—Erythema—Progesterone—uterine cancer	0.000256	0.00538	CcSEcCtD
Bimatoprost—Tension—Progesterone—uterine cancer	0.000251	0.00528	CcSEcCtD
Bimatoprost—Eye disorder—Medroxyprogesterone Acetate—uterine cancer	0.000249	0.00523	CcSEcCtD
Bimatoprost—Nervousness—Progesterone—uterine cancer	0.000248	0.00522	CcSEcCtD
Bimatoprost—Angiopathy—Medroxyprogesterone Acetate—uterine cancer	0.000242	0.00508	CcSEcCtD
Bimatoprost—Burning sensation—Epirubicin—uterine cancer	0.000241	0.00508	CcSEcCtD
Bimatoprost—Vision blurred—Progesterone—uterine cancer	0.000241	0.00507	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—GPX3—uterine cancer	0.00024	0.00962	CbGpPWpGaD
Bimatoprost—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00024	0.00505	CcSEcCtD
Bimatoprost—Keratitis—Doxorubicin—uterine cancer	0.000239	0.00503	CcSEcCtD
Bimatoprost—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.000232	0.00487	CcSEcCtD
Bimatoprost—Vertigo—Progesterone—uterine cancer	0.00023	0.00483	CcSEcCtD
Bimatoprost—Tension—Medroxyprogesterone Acetate—uterine cancer	0.000227	0.00478	CcSEcCtD
Bimatoprost—Palpitations—Progesterone—uterine cancer	0.000226	0.00475	CcSEcCtD
Bimatoprost—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.000225	0.00473	CcSEcCtD
Bimatoprost—Burning sensation—Doxorubicin—uterine cancer	0.000223	0.0047	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—CYP11A1—uterine cancer	0.000223	0.00893	CbGpPWpGaD
Bimatoprost—Cough—Progesterone—uterine cancer	0.000223	0.00469	CcSEcCtD
Bimatoprost—Scotoma—Epirubicin—uterine cancer	0.000221	0.00465	CcSEcCtD
Bimatoprost—Hypertension—Progesterone—uterine cancer	0.000221	0.00464	CcSEcCtD
Bimatoprost—Chest pain—Progesterone—uterine cancer	0.000218	0.00458	CcSEcCtD
Bimatoprost—Anxiety—Progesterone—uterine cancer	0.000217	0.00456	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.000216	0.00455	CcSEcCtD
Bimatoprost—Dry mouth—Progesterone—uterine cancer	0.000213	0.00448	CcSEcCtD
Bimatoprost—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000208	0.00438	CcSEcCtD
Bimatoprost—Infection—Progesterone—uterine cancer	0.000207	0.00436	CcSEcCtD
Bimatoprost—Stinging—Epirubicin—uterine cancer	0.000207	0.00435	CcSEcCtD
Bimatoprost—Pharyngitis—Dactinomycin—uterine cancer	0.000206	0.00433	CcSEcCtD
Bimatoprost—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.000205	0.00431	CcSEcCtD
Bimatoprost—Nervous system disorder—Progesterone—uterine cancer	0.000205	0.0043	CcSEcCtD
Bimatoprost—Scotoma—Doxorubicin—uterine cancer	0.000204	0.0043	CcSEcCtD
Bimatoprost—Skin disorder—Progesterone—uterine cancer	0.000203	0.00426	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000201	0.00804	CbGpPWpGaD
Bimatoprost—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000197	0.00415	CcSEcCtD
Bimatoprost—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.000197	0.00413	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.000196	0.00412	CcSEcCtD
Bimatoprost—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.000193	0.00406	CcSEcCtD
Bimatoprost—Stinging—Doxorubicin—uterine cancer	0.000192	0.00403	CcSEcCtD
Bimatoprost—Insomnia—Progesterone—uterine cancer	0.000189	0.00397	CcSEcCtD
Bimatoprost—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000188	0.00395	CcSEcCtD
Bimatoprost—Dyspnoea—Progesterone—uterine cancer	0.000186	0.00391	CcSEcCtD
Bimatoprost—Skin discolouration—Epirubicin—uterine cancer	0.000186	0.00391	CcSEcCtD
Bimatoprost—Somnolence—Progesterone—uterine cancer	0.000186	0.0039	CcSEcCtD
Bimatoprost—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000185	0.0039	CcSEcCtD
Bimatoprost—Dyspepsia—Progesterone—uterine cancer	0.000184	0.00386	CcSEcCtD
Bimatoprost—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000184	0.00386	CcSEcCtD
Bimatoprost—Cough increased—Epirubicin—uterine cancer	0.000183	0.00385	CcSEcCtD
Bimatoprost—Lacrimation increased—Epirubicin—uterine cancer	0.000182	0.00383	CcSEcCtD
Bimatoprost—Erythema—Dactinomycin—uterine cancer	0.000181	0.0038	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Progesterone—uterine cancer	0.00018	0.00379	CcSEcCtD
Bimatoprost—Pain—Progesterone—uterine cancer	0.000178	0.00375	CcSEcCtD
Bimatoprost—Inflammation—Epirubicin—uterine cancer	0.000173	0.00364	CcSEcCtD
Bimatoprost—Skin discolouration—Doxorubicin—uterine cancer	0.000172	0.00361	CcSEcCtD
Bimatoprost—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000171	0.0036	CcSEcCtD
Bimatoprost—Cough increased—Doxorubicin—uterine cancer	0.00017	0.00357	CcSEcCtD
Bimatoprost—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000169	0.00355	CcSEcCtD
Bimatoprost—Lacrimation increased—Doxorubicin—uterine cancer	0.000168	0.00354	CcSEcCtD
Bimatoprost—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000168	0.00354	CcSEcCtD
Bimatoprost—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000166	0.0035	CcSEcCtD
Bimatoprost—AKR1C3—Metapathway biotransformation—CYP19A1—uterine cancer	0.000164	0.00657	CbGpPWpGaD
Bimatoprost—Cystitis noninfective—Epirubicin—uterine cancer	0.000164	0.00345	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000163	0.00343	CcSEcCtD
Bimatoprost—Cystitis—Epirubicin—uterine cancer	0.000162	0.00341	CcSEcCtD
Bimatoprost—Inflammation—Doxorubicin—uterine cancer	0.00016	0.00337	CcSEcCtD
Bimatoprost—Dry eye—Epirubicin—uterine cancer	0.000155	0.00326	CcSEcCtD
Bimatoprost—Bladder pain—Epirubicin—uterine cancer	0.000152	0.00319	CcSEcCtD
Bimatoprost—Cystitis noninfective—Doxorubicin—uterine cancer	0.000152	0.00319	CcSEcCtD
Bimatoprost—Cystitis—Doxorubicin—uterine cancer	0.00015	0.00315	CcSEcCtD
Bimatoprost—Asthenia—Progesterone—uterine cancer	0.00015	0.00315	CcSEcCtD
Bimatoprost—Pruritus—Progesterone—uterine cancer	0.000148	0.00311	CcSEcCtD
Bimatoprost—Infection—Dactinomycin—uterine cancer	0.000147	0.00308	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000145	0.00581	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000145	0.00581	CbGpPWpGaD
Bimatoprost—Dry eye—Doxorubicin—uterine cancer	0.000143	0.00301	CcSEcCtD
Bimatoprost—Eye disorder—Etoposide—uterine cancer	0.00014	0.00295	CcSEcCtD
Bimatoprost—Bladder pain—Doxorubicin—uterine cancer	0.00014	0.00295	CcSEcCtD
Bimatoprost—Dizziness—Progesterone—uterine cancer	0.000138	0.0029	CcSEcCtD
Bimatoprost—Angiopathy—Etoposide—uterine cancer	0.000136	0.00287	CcSEcCtD
Bimatoprost—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000136	0.00285	CcSEcCtD
Bimatoprost—Mediastinal disorder—Etoposide—uterine cancer	0.000135	0.00285	CcSEcCtD
Bimatoprost—Eye pain—Epirubicin—uterine cancer	0.000135	0.00284	CcSEcCtD
Bimatoprost—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000134	0.00281	CcSEcCtD
Bimatoprost—Rash—Progesterone—uterine cancer	0.000132	0.00277	CcSEcCtD
Bimatoprost—Dermatitis—Progesterone—uterine cancer	0.000131	0.00276	CcSEcCtD
Bimatoprost—Headache—Progesterone—uterine cancer	0.000131	0.00275	CcSEcCtD
Bimatoprost—Pain—Dactinomycin—uterine cancer	0.000126	0.00265	CcSEcCtD
Bimatoprost—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000125	0.00263	CcSEcCtD
Bimatoprost—Eye pain—Doxorubicin—uterine cancer	0.000125	0.00262	CcSEcCtD
Bimatoprost—Nausea—Progesterone—uterine cancer	0.000124	0.00261	CcSEcCtD
Bimatoprost—Diplopia—Epirubicin—uterine cancer	0.000122	0.00256	CcSEcCtD
Bimatoprost—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.00251	CcSEcCtD
Bimatoprost—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.00251	CcSEcCtD
Bimatoprost—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000118	0.00249	CcSEcCtD
Bimatoprost—Vertigo—Etoposide—uterine cancer	0.000118	0.00247	CcSEcCtD
Bimatoprost—Cough—Etoposide—uterine cancer	0.000114	0.0024	CcSEcCtD
Bimatoprost—Hypertension—Etoposide—uterine cancer	0.000113	0.00238	CcSEcCtD
Bimatoprost—Diplopia—Doxorubicin—uterine cancer	0.000113	0.00237	CcSEcCtD
Bimatoprost—Liver function test abnormal—Epirubicin—uterine cancer	0.000112	0.00236	CcSEcCtD
Bimatoprost—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000112	0.00236	CcSEcCtD
Bimatoprost—Dry skin—Epirubicin—uterine cancer	0.000112	0.00235	CcSEcCtD
Bimatoprost—Chest pain—Etoposide—uterine cancer	0.000111	0.00234	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000111	0.00233	CcSEcCtD
Bimatoprost—Nasopharyngitis—Epirubicin—uterine cancer	0.000109	0.00229	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000107	0.00427	CbGpPWpGaD
Bimatoprost—Infection—Etoposide—uterine cancer	0.000106	0.00223	CcSEcCtD
Bimatoprost—Asthenia—Dactinomycin—uterine cancer	0.000106	0.00223	CcSEcCtD
Bimatoprost—Asthma—Epirubicin—uterine cancer	0.000105	0.00221	CcSEcCtD
Bimatoprost—Liver function test abnormal—Doxorubicin—uterine cancer	0.000104	0.00219	CcSEcCtD
Bimatoprost—Skin disorder—Etoposide—uterine cancer	0.000104	0.00218	CcSEcCtD
Bimatoprost—Dry skin—Doxorubicin—uterine cancer	0.000103	0.00217	CcSEcCtD
Bimatoprost—Bronchitis—Epirubicin—uterine cancer	0.000101	0.00213	CcSEcCtD
Bimatoprost—Nasopharyngitis—Doxorubicin—uterine cancer	0.000101	0.00212	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Epirubicin—uterine cancer	9.78e-05	0.00206	CcSEcCtD
Bimatoprost—Asthma—Doxorubicin—uterine cancer	9.74e-05	0.00205	CcSEcCtD
Bimatoprost—Dyspnoea—Etoposide—uterine cancer	9.52e-05	0.002	CcSEcCtD
Bimatoprost—Somnolence—Etoposide—uterine cancer	9.49e-05	0.002	CcSEcCtD
Bimatoprost—Bronchitis—Doxorubicin—uterine cancer	9.36e-05	0.00197	CcSEcCtD
Bimatoprost—Rash—Dactinomycin—uterine cancer	9.3e-05	0.00196	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Etoposide—uterine cancer	9.22e-05	0.00194	CcSEcCtD
Bimatoprost—Pain—Etoposide—uterine cancer	9.13e-05	0.00192	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Doxorubicin—uterine cancer	9.05e-05	0.0019	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—NDUFB11—uterine cancer	8.95e-05	0.00358	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—SRD5A2—uterine cancer	8.95e-05	0.00358	CbGpPWpGaD
Bimatoprost—Sinusitis—Epirubicin—uterine cancer	8.8e-05	0.00185	CcSEcCtD
Bimatoprost—Nausea—Dactinomycin—uterine cancer	8.76e-05	0.00184	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.69e-05	0.00348	CbGpPWpGaD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	8.59e-05	0.00344	CbGpPWpGaD
Bimatoprost—PTGER3—G alpha (i) signalling events—CXCL8—uterine cancer	8.54e-05	0.00342	CbGpPWpGaD
Bimatoprost—Rhinitis—Epirubicin—uterine cancer	8.44e-05	0.00178	CcSEcCtD
Bimatoprost—Pharyngitis—Epirubicin—uterine cancer	8.36e-05	0.00176	CcSEcCtD
Bimatoprost—AKR1C3—Disease—AKR1B10—uterine cancer	8.31e-05	0.00332	CbGpPWpGaD
Bimatoprost—Oedema peripheral—Epirubicin—uterine cancer	8.3e-05	0.00175	CcSEcCtD
Bimatoprost—Connective tissue disorder—Epirubicin—uterine cancer	8.28e-05	0.00174	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—AKR1B10—uterine cancer	8.24e-05	0.0033	CbGpPWpGaD
Bimatoprost—Sinusitis—Doxorubicin—uterine cancer	8.15e-05	0.00171	CcSEcCtD
Bimatoprost—Visual impairment—Epirubicin—uterine cancer	8.12e-05	0.00171	CcSEcCtD
Bimatoprost—Eye disorder—Epirubicin—uterine cancer	7.87e-05	0.00166	CcSEcCtD
Bimatoprost—Rhinitis—Doxorubicin—uterine cancer	7.81e-05	0.00164	CcSEcCtD
Bimatoprost—Pharyngitis—Doxorubicin—uterine cancer	7.74e-05	0.00163	CcSEcCtD
Bimatoprost—Oedema peripheral—Doxorubicin—uterine cancer	7.68e-05	0.00161	CcSEcCtD
Bimatoprost—Asthenia—Etoposide—uterine cancer	7.66e-05	0.00161	CcSEcCtD
Bimatoprost—Connective tissue disorder—Doxorubicin—uterine cancer	7.66e-05	0.00161	CcSEcCtD
Bimatoprost—Angiopathy—Epirubicin—uterine cancer	7.64e-05	0.00161	CcSEcCtD
Bimatoprost—Mediastinal disorder—Epirubicin—uterine cancer	7.59e-05	0.0016	CcSEcCtD
Bimatoprost—Pruritus—Etoposide—uterine cancer	7.55e-05	0.00159	CcSEcCtD
Bimatoprost—Visual impairment—Doxorubicin—uterine cancer	7.51e-05	0.00158	CcSEcCtD
Bimatoprost—Erythema—Epirubicin—uterine cancer	7.33e-05	0.00154	CcSEcCtD
Bimatoprost—Eye disorder—Doxorubicin—uterine cancer	7.28e-05	0.00153	CcSEcCtD
Bimatoprost—Tension—Epirubicin—uterine cancer	7.2e-05	0.00151	CcSEcCtD
Bimatoprost—Nervousness—Epirubicin—uterine cancer	7.12e-05	0.0015	CcSEcCtD
Bimatoprost—Angiopathy—Doxorubicin—uterine cancer	7.07e-05	0.00149	CcSEcCtD
Bimatoprost—Dizziness—Etoposide—uterine cancer	7.06e-05	0.00148	CcSEcCtD
Bimatoprost—Mediastinal disorder—Doxorubicin—uterine cancer	7.02e-05	0.00148	CcSEcCtD
Bimatoprost—Vision blurred—Epirubicin—uterine cancer	6.91e-05	0.00145	CcSEcCtD
Bimatoprost—AKR1C3—Disease—RNF43—uterine cancer	6.88e-05	0.00275	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—RNF43—uterine cancer	6.83e-05	0.00273	CbGpPWpGaD
Bimatoprost—PTGER3—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	6.79e-05	0.00272	CbGpPWpGaD
Bimatoprost—Erythema—Doxorubicin—uterine cancer	6.78e-05	0.00143	CcSEcCtD
Bimatoprost—Rash—Etoposide—uterine cancer	6.73e-05	0.00142	CcSEcCtD
Bimatoprost—Dermatitis—Etoposide—uterine cancer	6.73e-05	0.00141	CcSEcCtD
Bimatoprost—Headache—Etoposide—uterine cancer	6.69e-05	0.00141	CcSEcCtD
Bimatoprost—Tension—Doxorubicin—uterine cancer	6.66e-05	0.0014	CcSEcCtD
Bimatoprost—Nervousness—Doxorubicin—uterine cancer	6.59e-05	0.00139	CcSEcCtD
Bimatoprost—Vertigo—Epirubicin—uterine cancer	6.59e-05	0.00139	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—CCL2—uterine cancer	6.54e-05	0.00262	CbGpPWpGaD
Bimatoprost—Palpitations—Epirubicin—uterine cancer	6.48e-05	0.00136	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—STAR—uterine cancer	6.47e-05	0.00259	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—AKR1B1—uterine cancer	6.47e-05	0.00259	CbGpPWpGaD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	6.42e-05	0.00257	CbGpPWpGaD
Bimatoprost—Cough—Epirubicin—uterine cancer	6.4e-05	0.00135	CcSEcCtD
Bimatoprost—Vision blurred—Doxorubicin—uterine cancer	6.39e-05	0.00134	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	6.39e-05	0.00256	CbGpPWpGaD
Bimatoprost—Nausea—Etoposide—uterine cancer	6.34e-05	0.00133	CcSEcCtD
Bimatoprost—Hypertension—Epirubicin—uterine cancer	6.33e-05	0.00133	CcSEcCtD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	6.28e-05	0.00252	CbGpPWpGaD
Bimatoprost—Chest pain—Epirubicin—uterine cancer	6.24e-05	0.00131	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—INHBA—uterine cancer	6.24e-05	0.0025	CbGpPWpGaD
Bimatoprost—Anxiety—Epirubicin—uterine cancer	6.22e-05	0.00131	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	6.2e-05	0.0013	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—AKR1B10—uterine cancer	6.16e-05	0.00247	CbGpPWpGaD
Bimatoprost—Dry mouth—Epirubicin—uterine cancer	6.11e-05	0.00128	CcSEcCtD
Bimatoprost—Vertigo—Doxorubicin—uterine cancer	6.1e-05	0.00128	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—AKR1B10—uterine cancer	6.03e-05	0.00241	CbGpPWpGaD
Bimatoprost—Palpitations—Doxorubicin—uterine cancer	6e-05	0.00126	CcSEcCtD
Bimatoprost—Infection—Epirubicin—uterine cancer	5.95e-05	0.00125	CcSEcCtD
Bimatoprost—Cough—Doxorubicin—uterine cancer	5.92e-05	0.00125	CcSEcCtD
Bimatoprost—Nervous system disorder—Epirubicin—uterine cancer	5.87e-05	0.00123	CcSEcCtD
Bimatoprost—Hypertension—Doxorubicin—uterine cancer	5.86e-05	0.00123	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—AKR1B10—uterine cancer	5.82e-05	0.00233	CbGpPWpGaD
Bimatoprost—Skin disorder—Epirubicin—uterine cancer	5.81e-05	0.00122	CcSEcCtD
Bimatoprost—Chest pain—Doxorubicin—uterine cancer	5.78e-05	0.00121	CcSEcCtD
Bimatoprost—Anxiety—Doxorubicin—uterine cancer	5.76e-05	0.00121	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	5.74e-05	0.00121	CcSEcCtD
Bimatoprost—AKR1C3—Disease—AKR1C1—uterine cancer	5.67e-05	0.00227	CbGpPWpGaD
Bimatoprost—Dry mouth—Doxorubicin—uterine cancer	5.65e-05	0.00119	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—AKR1C1—uterine cancer	5.62e-05	0.00225	CbGpPWpGaD
Bimatoprost—Infection—Doxorubicin—uterine cancer	5.5e-05	0.00116	CcSEcCtD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	5.5e-05	0.0022	CbGpPWpGaD
Bimatoprost—Nervous system disorder—Doxorubicin—uterine cancer	5.43e-05	0.00114	CcSEcCtD
Bimatoprost—Insomnia—Epirubicin—uterine cancer	5.41e-05	0.00114	CcSEcCtD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	5.38e-05	0.00215	CbGpPWpGaD
Bimatoprost—Skin disorder—Doxorubicin—uterine cancer	5.38e-05	0.00113	CcSEcCtD
Bimatoprost—Dyspnoea—Epirubicin—uterine cancer	5.34e-05	0.00112	CcSEcCtD
Bimatoprost—Somnolence—Epirubicin—uterine cancer	5.32e-05	0.00112	CcSEcCtD
Bimatoprost—Dyspepsia—Epirubicin—uterine cancer	5.27e-05	0.00111	CcSEcCtD
Bimatoprost—PTGER3—GPCR ligand binding—CXCL8—uterine cancer	5.17e-05	0.00207	CbGpPWpGaD
Bimatoprost—Gastrointestinal disorder—Epirubicin—uterine cancer	5.17e-05	0.00109	CcSEcCtD
Bimatoprost—Pain—Epirubicin—uterine cancer	5.12e-05	0.00108	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—RNF43—uterine cancer	5.1e-05	0.00204	CbGpPWpGaD
Bimatoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	5.08e-05	0.00203	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—POLD1—uterine cancer	5.07e-05	0.00203	CbGpPWpGaD
Bimatoprost—Insomnia—Doxorubicin—uterine cancer	5.01e-05	0.00105	CcSEcCtD
Bimatoprost—PTGER1—Signaling Pathways—RNF43—uterine cancer	5e-05	0.002	CbGpPWpGaD
Bimatoprost—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	4.97e-05	0.00199	CbGpPWpGaD
Bimatoprost—Dyspnoea—Doxorubicin—uterine cancer	4.94e-05	0.00104	CcSEcCtD
Bimatoprost—Somnolence—Doxorubicin—uterine cancer	4.92e-05	0.00104	CcSEcCtD
Bimatoprost—AKR1C3—Disease—DCN—uterine cancer	4.9e-05	0.00196	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—CCL2—uterine cancer	4.89e-05	0.00196	CbGpPWpGaD
Bimatoprost—Dyspepsia—Doxorubicin—uterine cancer	4.87e-05	0.00103	CcSEcCtD
Bimatoprost—PTGFR—G alpha (q) signalling events—PIK3CA—uterine cancer	4.86e-05	0.00195	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—RNF43—uterine cancer	4.82e-05	0.00193	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR ligand binding—CCL2—uterine cancer	4.79e-05	0.00192	CbGpPWpGaD
Bimatoprost—Gastrointestinal disorder—Doxorubicin—uterine cancer	4.78e-05	0.00101	CcSEcCtD
Bimatoprost—PTGER1—G alpha (q) signalling events—PIK3CA—uterine cancer	4.76e-05	0.0019	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—AKR1C1—uterine cancer	4.75e-05	0.0019	CbGpPWpGaD
Bimatoprost—Pain—Doxorubicin—uterine cancer	4.74e-05	0.000996	CcSEcCtD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	4.73e-05	0.00189	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—INHBA—uterine cancer	4.67e-05	0.00187	CbGpPWpGaD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	4.63e-05	0.00185	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—INHBA—uterine cancer	4.57e-05	0.00183	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—INHBA—uterine cancer	4.41e-05	0.00176	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	4.35e-05	0.00174	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—AKR1C3—uterine cancer	4.33e-05	0.00173	CbGpPWpGaD
Bimatoprost—Asthenia—Epirubicin—uterine cancer	4.29e-05	0.000903	CcSEcCtD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	4.26e-05	0.0017	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—HMGA1—uterine cancer	4.25e-05	0.0017	CbGpPWpGaD
Bimatoprost—Pruritus—Epirubicin—uterine cancer	4.23e-05	0.00089	CcSEcCtD
Bimatoprost—AKR1C3—Metabolism—RRM2—uterine cancer	4.23e-05	0.00169	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PGR—uterine cancer	4.22e-05	0.00169	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—AKR1C1—uterine cancer	4.2e-05	0.00168	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—AKR1C1—uterine cancer	4.11e-05	0.00165	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—DCN—uterine cancer	4.11e-05	0.00164	CbGpPWpGaD
Bimatoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	4.02e-05	0.00161	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—YWHAE—uterine cancer	4.02e-05	0.00161	CbGpPWpGaD
Bimatoprost—Asthenia—Doxorubicin—uterine cancer	3.97e-05	0.000836	CcSEcCtD
Bimatoprost—AKR1C3—Signaling Pathways—AKR1C1—uterine cancer	3.97e-05	0.00159	CbGpPWpGaD
Bimatoprost—Dizziness—Epirubicin—uterine cancer	3.96e-05	0.000832	CcSEcCtD
Bimatoprost—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	3.94e-05	0.00158	CbGpPWpGaD
Bimatoprost—Pruritus—Doxorubicin—uterine cancer	3.92e-05	0.000824	CcSEcCtD
Bimatoprost—AKR1C3—Disease—FBXW7—uterine cancer	3.89e-05	0.00156	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—CYP11A1—uterine cancer	3.87e-05	0.00155	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR ligand binding—CXCL8—uterine cancer	3.87e-05	0.00155	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—FBXW7—uterine cancer	3.86e-05	0.00154	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR ligand binding—CXCL8—uterine cancer	3.78e-05	0.00151	CbGpPWpGaD
Bimatoprost—Rash—Epirubicin—uterine cancer	3.77e-05	0.000794	CcSEcCtD
Bimatoprost—Dermatitis—Epirubicin—uterine cancer	3.77e-05	0.000793	CcSEcCtD
Bimatoprost—Headache—Epirubicin—uterine cancer	3.75e-05	0.000788	CcSEcCtD
Bimatoprost—Dizziness—Doxorubicin—uterine cancer	3.66e-05	0.00077	CcSEcCtD
Bimatoprost—Nausea—Epirubicin—uterine cancer	3.55e-05	0.000748	CcSEcCtD
Bimatoprost—Rash—Doxorubicin—uterine cancer	3.49e-05	0.000734	CcSEcCtD
Bimatoprost—Dermatitis—Doxorubicin—uterine cancer	3.49e-05	0.000734	CcSEcCtD
Bimatoprost—Headache—Doxorubicin—uterine cancer	3.47e-05	0.00073	CcSEcCtD
Bimatoprost—PTGER3—Signaling Pathways—STK11—uterine cancer	3.37e-05	0.00135	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—CCL2—uterine cancer	3.36e-05	0.00134	CbGpPWpGaD
Bimatoprost—Nausea—Doxorubicin—uterine cancer	3.29e-05	0.000692	CcSEcCtD
Bimatoprost—PTGFR—Signaling Pathways—AKR1C3—uterine cancer	3.24e-05	0.00129	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—AKR1C3—uterine cancer	3.17e-05	0.00127	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—SOCS3—uterine cancer	3.16e-05	0.00126	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PGR—uterine cancer	3.15e-05	0.00126	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PGR—uterine cancer	3.09e-05	0.00124	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—CDKN2B—uterine cancer	3.05e-05	0.00122	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CDKN2B—uterine cancer	3.02e-05	0.00121	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—YWHAE—uterine cancer	3.01e-05	0.0012	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PGR—uterine cancer	2.98e-05	0.00119	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—YWHAE—uterine cancer	2.94e-05	0.00118	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—IGF1R—uterine cancer	2.93e-05	0.00117	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—CXCL8—uterine cancer	2.92e-05	0.00117	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—FBXW7—uterine cancer	2.88e-05	0.00115	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—CYP19A1—uterine cancer	2.85e-05	0.00114	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—STK11—uterine cancer	2.85e-05	0.00114	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—YWHAE—uterine cancer	2.84e-05	0.00114	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—FBXW7—uterine cancer	2.82e-05	0.00113	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—SMAD3—uterine cancer	2.78e-05	0.00111	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—SMAD3—uterine cancer	2.76e-05	0.0011	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—FBXW7—uterine cancer	2.72e-05	0.00109	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.67e-05	0.00107	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—FGFR2—uterine cancer	2.65e-05	0.00106	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—CXCL8—uterine cancer	2.65e-05	0.00106	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—FGFR2—uterine cancer	2.63e-05	0.00105	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—MTHFR—uterine cancer	2.55e-05	0.00102	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.55e-05	0.00102	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—STK11—uterine cancer	2.52e-05	0.00101	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—CCL2—uterine cancer	2.51e-05	0.001	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—STK11—uterine cancer	2.47e-05	0.000987	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—CCL2—uterine cancer	2.46e-05	0.000983	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—STK11—uterine cancer	2.38e-05	0.000953	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—SOCS3—uterine cancer	2.36e-05	0.000945	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SOCS3—uterine cancer	2.31e-05	0.000925	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CDKN2B—uterine cancer	2.26e-05	0.000904	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—ESR1—uterine cancer	2.25e-05	0.000901	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SOCS3—uterine cancer	2.23e-05	0.000892	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CDKN2B—uterine cancer	2.21e-05	0.000885	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—IGF1R—uterine cancer	2.19e-05	0.000878	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—CXCL8—uterine cancer	2.18e-05	0.000874	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—IGF1R—uterine cancer	2.15e-05	0.00086	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—MTHFR—uterine cancer	2.14e-05	0.000856	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—CXCL8—uterine cancer	2.14e-05	0.000856	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CDKN2B—uterine cancer	2.13e-05	0.000854	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—NRAS—uterine cancer	2.13e-05	0.000852	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—IGF1R—uterine cancer	2.07e-05	0.000829	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—SMAD3—uterine cancer	2.06e-05	0.000826	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—SMAD3—uterine cancer	2.02e-05	0.000808	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—CXCL8—uterine cancer	1.98e-05	0.000794	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CCL2—uterine cancer	1.98e-05	0.000793	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—FGFR2—uterine cancer	1.97e-05	0.000788	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—SMAD3—uterine cancer	1.95e-05	0.00078	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—CXCL8—uterine cancer	1.94e-05	0.000777	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—FGFR2—uterine cancer	1.93e-05	0.000771	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.89e-05	0.000754	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—FGFR2—uterine cancer	1.86e-05	0.000744	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—PIK3CA—uterine cancer	1.85e-05	0.000742	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—KRAS—uterine cancer	1.83e-05	0.000733	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—ESR1—uterine cancer	1.68e-05	0.000674	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—PIK3CA—uterine cancer	1.68e-05	0.000674	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—ERBB2—uterine cancer	1.67e-05	0.000667	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—ERBB2—uterine cancer	1.65e-05	0.000661	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—ESR1—uterine cancer	1.65e-05	0.00066	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—NRAS—uterine cancer	1.59e-05	0.000637	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—ESR1—uterine cancer	1.59e-05	0.000636	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CXCL8—uterine cancer	1.57e-05	0.000627	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—NRAS—uterine cancer	1.56e-05	0.000623	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—HRAS—uterine cancer	1.56e-05	0.000623	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—CDKN1B—uterine cancer	1.54e-05	0.000618	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CDKN1B—uterine cancer	1.53e-05	0.000613	CbGpPWpGaD
Bimatoprost—PTGER3—GPCR downstream signaling—AKT1—uterine cancer	1.51e-05	0.000606	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CCL2—uterine cancer	1.48e-05	0.000593	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—CTNNB1—uterine cancer	1.46e-05	0.000584	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CCL2—uterine cancer	1.45e-05	0.000581	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—CTNNB1—uterine cancer	1.45e-05	0.000579	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PTEN—uterine cancer	1.42e-05	0.000569	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PTEN—uterine cancer	1.41e-05	0.000564	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CCL2—uterine cancer	1.4e-05	0.00056	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—PIK3CA—uterine cancer	1.39e-05	0.000555	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling by GPCR—AKT1—uterine cancer	1.37e-05	0.00055	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—KRAS—uterine cancer	1.37e-05	0.000548	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—PIK3CA—uterine cancer	1.36e-05	0.000543	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—EP300—uterine cancer	1.36e-05	0.000542	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—EP300—uterine cancer	1.34e-05	0.000538	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—KRAS—uterine cancer	1.34e-05	0.000537	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—VEGFA—uterine cancer	1.27e-05	0.000509	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—NRAS—uterine cancer	1.27e-05	0.000507	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—PIK3CA—uterine cancer	1.26e-05	0.000504	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—NRAS—uterine cancer	1.26e-05	0.000503	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—ERBB2—uterine cancer	1.24e-05	0.000495	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—PIK3CA—uterine cancer	1.23e-05	0.000493	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—ERBB2—uterine cancer	1.21e-05	0.000484	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PTEN—uterine cancer	1.19e-05	0.000476	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CXCL8—uterine cancer	1.17e-05	0.000469	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—ERBB2—uterine cancer	1.17e-05	0.000467	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—HRAS—uterine cancer	1.16e-05	0.000466	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CXCL8—uterine cancer	1.15e-05	0.000459	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CDKN1B—uterine cancer	1.14e-05	0.000458	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—HRAS—uterine cancer	1.14e-05	0.000456	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—EP300—uterine cancer	1.13e-05	0.000454	CbGpPWpGaD
Bimatoprost—PTGFR—GPCR downstream signaling—AKT1—uterine cancer	1.13e-05	0.000453	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CDKN1B—uterine cancer	1.12e-05	0.000448	CbGpPWpGaD
Bimatoprost—PTGER1—GPCR downstream signaling—AKT1—uterine cancer	1.11e-05	0.000443	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CXCL8—uterine cancer	1.11e-05	0.000443	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—KRAS—uterine cancer	1.09e-05	0.000437	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—KRAS—uterine cancer	1.08e-05	0.000433	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—CTNNB1—uterine cancer	1.08e-05	0.000433	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CDKN1B—uterine cancer	1.08e-05	0.000433	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—CTNNB1—uterine cancer	1.06e-05	0.000424	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PTEN—uterine cancer	1.05e-05	0.000422	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PTEN—uterine cancer	1.03e-05	0.000413	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling by GPCR—AKT1—uterine cancer	1.03e-05	0.000411	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—CTNNB1—uterine cancer	1.02e-05	0.000409	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling by GPCR—AKT1—uterine cancer	1.01e-05	0.000403	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—EP300—uterine cancer	1e-05	0.000402	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—PIK3CA—uterine cancer	1e-05	0.000401	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PTEN—uterine cancer	9.95e-06	0.000398	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—PIK3CA—uterine cancer	9.94e-06	0.000398	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—EP300—uterine cancer	9.84e-06	0.000394	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—TP53—uterine cancer	9.62e-06	0.000385	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—VEGFA—uterine cancer	9.52e-06	0.000381	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—EP300—uterine cancer	9.49e-06	0.00038	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—NRAS—uterine cancer	9.4e-06	0.000376	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—VEGFA—uterine cancer	9.32e-06	0.000373	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—HRAS—uterine cancer	9.28e-06	0.000371	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—NRAS—uterine cancer	9.2e-06	0.000368	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—HRAS—uterine cancer	9.2e-06	0.000368	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—VEGFA—uterine cancer	8.99e-06	0.00036	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—NRAS—uterine cancer	8.88e-06	0.000355	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—PIK3CA—uterine cancer	8.4e-06	0.000336	CbGpPWpGaD
Bimatoprost—AKR1C3—Disease—AKT1—uterine cancer	8.19e-06	0.000328	CbGpPWpGaD
Bimatoprost—PTGER3—Signaling Pathways—AKT1—uterine cancer	8.12e-06	0.000325	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—KRAS—uterine cancer	8.09e-06	0.000324	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—KRAS—uterine cancer	7.92e-06	0.000317	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—KRAS—uterine cancer	7.64e-06	0.000306	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—PIK3CA—uterine cancer	7.43e-06	0.000298	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—PIK3CA—uterine cancer	7.28e-06	0.000291	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—TP53—uterine cancer	7.19e-06	0.000288	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—TP53—uterine cancer	7.04e-06	0.000282	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—PIK3CA—uterine cancer	7.02e-06	0.000281	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—HRAS—uterine cancer	6.88e-06	0.000275	CbGpPWpGaD
Bimatoprost—AKR1C3—Metabolism—AKT1—uterine cancer	6.86e-06	0.000274	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—TP53—uterine cancer	6.79e-06	0.000272	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—HRAS—uterine cancer	6.73e-06	0.000269	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—HRAS—uterine cancer	6.5e-06	0.00026	CbGpPWpGaD
Bimatoprost—PTGFR—Signaling Pathways—AKT1—uterine cancer	6.07e-06	0.000243	CbGpPWpGaD
Bimatoprost—PTGER1—Signaling Pathways—AKT1—uterine cancer	5.94e-06	0.000238	CbGpPWpGaD
Bimatoprost—AKR1C3—Signaling Pathways—AKT1—uterine cancer	5.74e-06	0.00023	CbGpPWpGaD
